Ovid Therapeutics Inc. (OVID)

Compare

0.3241

-0.0159

(-4.68%)

As of 12:46:41 PM EDT. Market Open.

Ovid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that Meg Alexander, President and Chief Operating Officer, will present at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025, at 8:45 AM. ET. A live webcast of the Needham Virtual Healthcare Conference presentation can be accessed through the Events & Present

GlobeNewswire yesterday

OVID
-4.68%
Ovid Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Ovid Therapeutics ( NASDAQ:OVID ) Full Year 2024 Results Key Financial Results Net loss: US$26.4m (loss narrowed by 50...

Simply Wall St. 22 days ago

OVID
-4.68%
Ovid Therapeutics (OVID) Reports Q4 Loss, Lags Revenue Estimates

Ovid Therapeutics (OVID) delivered earnings and revenue surprises of 18.75% and 45.71%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 23 days ago

OVID
-4.68%
Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Stelios Papadopolous, Ph.D., a pioneering leader in biotech, appointed to Board of Directors; two industry veterans joined management team as Ovid prepares to take OV329 into patient trials and move its first KCC2 direct activator into the clinicTopline results from Phase 1 study of OV329 expected in Q3 2025, which will include biomarkers that measure clinical effect and target engagement, safety, and tolerabilityOV350, Ovid’s first program in its KCC2 direct activator library, initiated a first

GlobeNewswire 23 days ago

OVID
-4.68%
We're A Little Worried About Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Simply Wall St. 23 days ago

OVID
-4.68%
Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors

NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need, today announced the appointment of Stelios Papadopoulos, Ph.D. to its Board of Directors. “Stelios is a pioneering force in biotechnology. His vision and strategic acumen have shaped the landscape of our industry—building companies, financing breakthroughs, and enabling transformative med

GlobeNewswire last month

OVID
-4.68%
Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that Meg Alexander, President and Chief Operating Officer, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 3:10 p.m. ET in Boston, Massachusetts. A live webcast of the TD Cowen presentation can be accessed through the Events & Presentations sec

GlobeNewswire last month

OVID
-4.68%
Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that management will participate in a virtual presentation at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12, 2025, at 4:00 p.m. ET. A live webcast of the presentation can be accessed through the Events & Presentations section of the Company’s we

GlobeNewswire last month

OVID
-4.68%
Ovid Therapeutics upgraded at Oppenheimer as OV329’s promise ‘quite real’

Oppenheimer upgraded Ovid Therapeutics (OVID) to Outperform from Perform with a $4 price target The firm says OV329’s promise is “quite real” as a potential best-in-class next-generation GABA-AT inhibitor, telling investors that OV329 has shown over 100x potency over first-generation GABA-AT inhibitor vigabatrin and has been designed to avoid ocular toxicity. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recomme

TipRanks 2 months ago

OVID
-4.68%
US Penny Stocks To Watch In January 2025

As the U.S. stock market navigates a landscape marked by the Federal Reserve's decision to keep interest rates steady, investors remain focused on forthcoming big-tech earnings reports. Amid these broader market dynamics, penny stocks continue to capture attention for their potential to offer affordability and growth opportunities. Despite being considered an outdated term, penny stocks—often representing smaller or newer companies—can still be relevant investment options when supported by...

Simply Wall St. 2 months ago

HUIZ

OVID
-4.68%
HLVX
Ovid Therapeutics Insider Ups Holding During Year

From what we can see, insiders were net buyers in Ovid Therapeutics Inc.'s ( NASDAQ:OVID ) during the past 12 months...

Simply Wall St. 2 months ago

OVID
-4.68%
3 US Penny Stocks With Market Caps Over $20M

As the U.S. stock market experiences a downturn, with the S&P 500 on track to end its three-week winning streak, investors are keenly observing opportunities across various sectors. Penny stocks, though often associated with riskier ventures, continue to capture attention due to their potential for substantial returns when backed by strong financials and growth prospects. This article explores three penny stocks that stand out for their solid balance sheets and potential for growth, offering...

Simply Wall St. 3 months ago

DAIO

PXLW

OVID
-4.68%
Ovid Therapeutics to Present Multiple Posters Supporting Its Pipeline Programs Targeting Neuronal Hyperexcitability at the American Epilepsy Society 2024 Annual Meeting

Two preclinical studies to be presented on OV329, a potential next-generation GABA aminotransferase inhibitor, highlighting its safety profile and lack of ocular accumulation relative to vigabatrin Findings to be presented on the effects of OV329 on elevating GABA and suppressing seizures as evaluated in the lithium-pilocarpine model of status epilepticus A study of the effect of OV350, a KCC2 direct activator, in rescuing animals from nerve agent-induced benzodiazepine-resistant refractory stat

GlobeNewswire 3 months ago

OVID
-4.68%
Ovid Therapeutics (OVID) Reports Q3 Loss, Tops Revenue Estimates

Ovid Therapeutics (OVID) delivered earnings and revenue surprises of -5.26% and 15.33%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 4 months ago

OVID
-4.68%
Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results

A Phase 1 SAD/MAD study of OV329 is progressing as planned, and based on encouraging human safety data to date, Ovid will engage regulators about adding cohorts to increase potential dosing opportunities for Phase 2 programs.A regulatory application for a Phase 1 trial of OV350, the first candidate from Ovid's KCC2 direct activator library, is expected to be filed in Q4 2024.The Company will host a KCC2 Download Day on November 13 to provide updates on Ovid's platform of KCC2 direct activators a

GlobeNewswire 4 months ago

OVID
-4.68%
US Penny Stocks To Watch This November 2024

As the U.S. stock market continues to rally post-election, with major indices like the S&P 500 and Nasdaq reaching record highs, investors are exploring various opportunities in different corners of the market. Penny stocks, often associated with smaller or newer companies, remain a relevant investment area despite their somewhat outdated moniker. These stocks can offer potential for growth at lower price points when backed by strong financials and fundamentals, presenting intriguing...

Simply Wall St. 4 months ago

INVZ

INVZW

OVID
-4.68%
Ovid Therapeutics to Host Investor Event

KCC2 Download Day on Wednesday, November 13, 2024NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today announced that it will host an investor event focused on its portfolio of direct potassium chloride co-transporter 2 (KCC2) activators on Wednesday, November 13, 2024. The event will take place at Ovid’s headquarters in New York’s Hudson Yar

GlobeNewswire 4 months ago

OVID
-4.68%
Will Ovid Therapeutics (NASDAQ:OVID) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Simply Wall St. 5 months ago

OVID
-4.68%
Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with Vigabatrin

Study found OV329 cleared and remained undetectable in the retina, eye, and brain tissues of mice, unlike vigabatrin which has repeatedly shown to preferentially accumulate in mouse retinas, eyes, and other tissues OV329’s potency, mechanism of inhibition, short half-life, rapid tissue elimination and prolonged pharmacodynamic effect suggests it delivers a differentiated ocular safety and efficacy profile from vigabatrin A Phase 1 trial evaluating OV329 in healthy volunteers is on-track for comp

GlobeNewswire 6 months ago

OVID
-4.68%
After epilepsy setback, Ovid charges confidently ahead in CNS

A promising epilepsy drug Ovid sold to Takeda recently missed the mark in late-stage trials. But Ovid believes it has other novel mechanisms that could deliver a CNS win.

Pharma Voice 6 months ago

OVID
-4.68%
TAK

Performance Overview

Return	OVID	S&P 500 (^GSPC)
YTD	-65.30%	-7.12%
1-Year	-89.37%	+4.82%
3-Year	-89.90%	+20.17%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Live

Ovid Therapeutics Inc. (OVID)

Ovid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

Ovid Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Ovid Therapeutics (OVID) Reports Q4 Loss, Lags Revenue Estimates

Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results

We're A Little Worried About Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Rate

Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors

Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Ovid Therapeutics upgraded at Oppenheimer as OV329’s promise ‘quite real’

US Penny Stocks To Watch In January 2025

Ovid Therapeutics Insider Ups Holding During Year

3 US Penny Stocks With Market Caps Over $20M

Ovid Therapeutics to Present Multiple Posters Supporting Its Pipeline Programs Targeting Neuronal Hyperexcitability at the American Epilepsy Society 2024 Annual Meeting

Ovid Therapeutics (OVID) Reports Q3 Loss, Tops Revenue Estimates

Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results

US Penny Stocks To Watch This November 2024

Ovid Therapeutics to Host Investor Event

Will Ovid Therapeutics (NASDAQ:OVID) Spend Its Cash Wisely?

Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with Vigabatrin

After epilepsy setback, Ovid charges confidently ahead in CNS

Performance Overview